The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis by Bohte, Anneloes E. et al.
GASTROINTESTINAL
The diagnostic accuracy of US, CT, MRI and
1H-MRS
for the evaluation of hepatic steatosis compared
with liver biopsy: a meta-analysis
Anneloes E. Bohte & Jochem R. van Werven &
Shandra Bipat & Jaap Stoker
Received: 9 April 2010 /Revised: 24 May 2010 /Accepted: 14 June 2010 /Published online: 31 July 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Objective To meta-analyse the diagnostic accuracy of US,
CT, MRI and
1H-MRS for the evaluation of hepatic
steatosis.
Methods From a comprehensive literature search in
MEDLINE, EMBASE, CINAHL and Cochrane (up to
November 2009), articles were selected that investigated
the diagnostic performance imaging techniques for
evaluating hepatic steatosis with histopathology as the
reference standard. Cut-off values for the presence of
steatosis on liver biopsy were subdivided into four
groups: (1) >0, >2 and >5% steatosis; (2) >10, >15 and
>20%; (3) >25, >30 and >33%; (4) >50, >60 and >66%.
Per group, summary estimates for sensitivity and specificity
were calculated. The natural-logarithm of the diagnostic odds
ratio (lnDOR) was used as a single indicator of test
performance.
Results 46 articles were included. Mean sensitivity estimates
for subgroups were 73.3–90.5% (US), 46.1–72.0% (CT),
82.0–97.4% (MRI) and 72.7–88.5% (
1H-MRS). Mean
specificity ranges were 69.6–85.2% (US), 88.1–94.6%
(CT), 76.1–95.3% (MRI) and 92.0–95.7% (
1H-MRS).
Overall performance (lnDOR) of MRI and
1H-MRS was
better than that for US and CT for all subgroups, with
significant differences in groups 1 and 2.
Conclusion MRI and
1H-MRS can be considered techniques
of choice for accurate evaluation of hepatic steatosis.
Keywords Hepatic steatosis.Diagnostic accuracy.
Magnetic resonance imaging.Magnetic resonance
spectroscopy.Computed tomography.Ultrasonography
Introduction
The prevalence of hepatic steatosis is increasing rapidly
worldwide. This is largely attributed to the association with
obesity and insulin resistance in non-alcoholic fatty liver
disease (NAFLD) [1, 2].
Detection and quantification of hepatic steatosis is
clinically important. In NAFLD, steatosis is the hepatic
manifestation of the metabolic syndrome and the earliest
biomarker for the development of liver fibrosis in the more
severe condition of non-alcoholic steatohepatitis (NASH).
Early diagnosis and treatment of NASH can prevent the
potential development of cirrhosis and hepatocellular
carcinoma (HCC) [3–5]. In hepatitis C, steatosis is
associated with more severe fibrosis and rapid disease
progression [6, 7]. In liver transplantation surgery, the
presence of steatosis impairs the regenerative capacity of
the liver in both donor and recipient [8, 9].
Liver biopsy remains the reference test for the evaluation
of hepatic steatosis, despite well-established drawbacks
regarding its invasiveness and sampling error due to small
sample size and inter-observer variability [10].
Many studies have focused on the role of imaging
techniques as a non-invasive alternative to liver biopsy for
detecting and quantifying hepatic steatosis [11–13]. The
reported sensitivities and specificities between different
imaging techniques and between different studies investi-
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magnetic resonance spectroscopy (
1H-MRS)—generally
considered the best technique—is increasingly used as a
reference standard instead of liver biopsy, no evidence-
based consensus currently exists on this topic.
The purpose of this systematic review therefore was to
summarise the available literature on the accuracy of
ultrasound (US), computed tomography (CT), magnetic
resonance imaging (MRI) and
1H-MRS for the evaluation
of hepatic steatosis with histopathology as the reference
test. Subsequently, we aimed to identify the most accurate
technique by meta-analysis.
Materials and methods
Literature search and study selection
We searched the MEDLINE (January 1966–November
2009), EMBASE (January 1980–November 2009),
CINAHL and Cochrane databases without language restric-
tions with the assistance of an experienced clinical
librarian. We combined Medical Subject Headings (MeSH)
terms and accompanying entry terms for the patient group
(patients with hepatic steatosis) and the index test (US, CT,
MRI,
1H-MRS). The search strategy is described in detail in
Online Resource 1.
Two reviewers (A.B. and J.v.W) read the titles and
abstracts of all the articles obtained to select potentially
relevant papers (original papers that addressed the diagnos-
tic accuracy of US, CT, MRI or
1H-MRS for detecting
hepatic steatosis in humans with histopathology as the
reference test in ≥10 individuals). The reference lists of
selected papers and of narrative reviews were screened for
search completion.
The full texts of potentially relevant papers were reviewed
for inclusion by the same reviewers independently. Inclusion
criteria were: (a) hepatic steatosis was evaluated with US,
CT, MRI and/or
1H-MRS; (b) imaging techniques met the
minimum technical requirements of grey scale and real
time for US; ≤120 kV for CT and ≥1T e s l af o rM R I ;(c)
histopathology as the reference test; (d) evaluation of ≥10
human individuals; (e) criteria for a positive index test
were clearly explained; (f) examination method of stea-
tosis on liver biopsy was clearly explained; (g) data on
diagnostic accuracy were reported. Exclusion criteria
were: (a) duplicate publication; (b) reporting of combined
data for different imaging techniques or data on the single
technique could not be extracted; (c) no original research.
Papers were not blinded with regard to authors’ names,
affiliations or journal. The reviewers resolved all disagree-
ments about inclusion and data extraction by consensus
after face-to-face discussion.
Data extraction
From the articles included, the reviewers (A.B. and J.v.W.)
independently recorded data using a standardised form.
Papers were translated if necessary.
Methodological quality Methodological quality was
assessed based on the Quality Assessment of Studies of
Diagnostic Accuracy included in Systematic Reviews
(QUADAS) guidelines [14]. To be reasonably sure that
the condition of the liver did not change between the two
tests we chose a period of 1 month as a quality indicator
[15, 16]. Additionally, we noted whether the study design
was prospective or retrospective.
Patient characteristics For each study, we extracted data on
(a) sample size; (b) male-female ratio; (c) patient age; (d)
body mass index (BMI) and (e) patient spectrum.
Imaging features and evaluation For each imaging tech-
nique we recorded (a) the number of patients; (b) the
criteria used for steatosis evaluation and (c) the cut-off
values used. We noted whether cut-off values were defined
prospectively or retrospectively. Additionally, for US we
noted the type and frequency of the probe(s) used. For CT
we noted: (a) the type of CTand (b) the imaging parameters
(kV and mAs). For MRI, we noted: (a) magnetic field
strength; (b) imaging sequence; (c) imaging parameters
used;( d )whether breath holds were used; and (e)
correction for T2* effects. For
1H-MRS, we noted: (a)
magnetic field strength; (b) imaging sequence; (c) imaging
parameters; (d) voxel size; (e) whether breath holds were
used and (f) correction for T1 or T2 effects.
Reference test For liver biopsy we included data on: (a) the
number of patients biopsied; (b) cut-off values for steatosis
grades and whether the presence of (c) fibrosis (d)
inflammation and (e) iron was evaluated in the biopsy
specimen.
Data for calculation of diagnostic accuracy We extracted
available data on true-positives (TP), false-negatives (FN),
false-positives (FP) and true-negatives (TN) for detecting
steatosis with the selected imaging technique to construct
2×2 contingency tables. Available 3×3 and 4×4 tables
were dichotomised. Many different cut-off values for
positive results (steatosis present) on liver biopsy were
compared to the imaging techniques. We therefore grouped
accuracy results from cut-off values that were almost equal
into four subgroups to enable meta-analysis:
Group 1: Cut-off values of >0%, >2% and >5% steatosis
on biopsy;
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steatosis on biopsy;
Group 3: Cut-off values of >25%, >30% and >33%
steatosis on biopsy and the qualitative designa-
tion of “moderate or severe” steatosis;
Group 4: Cut-off values of >50%, >60% and >66%
steatosis on biopsy and the qualitative designa-
tion of “severe” steatosis.
During analysis we corrected for dependent data such as
results presented for different readers or for multiple
imaging techniques within one study population. For CT
and MRI, we did not use data obtained by subjective visual
evaluation of examinations for analysis. If raw data in terms
of 2×2 tables were unavailable, we attempted to contact
authors for completion or verification of data.
Data analysis
We performedbivariate random-effects analysis forthepooled
sensitivities and specificities per cut-off value group for each
imagingtechnique [17]. In this analysis, the logit-transformed
sensitivities and logit-transformed specificities from individ-
ual studies in a meta-analysis are assumed to follow a
bivariate normal distribution around a mean logit sensitivity
and a mean logit specificity. After antilogit transformation,
summary estimates of sensitivity and specificity with 95%
confidence intervals were calculated. Additionally, we calcu-
lated the natural logarithm (ln) of the diagnostic odds ratio
(DOR): [logit sensitivity + logit specificity]. The DOR is a
single indicator of test performance [18]. A higher lnDOR
value indicates a better discriminatory test performance. If the
lnDOR is not significantly different from 0, a test does not
discriminate between patients with the disorder and those
without it. We performed z-tests to compare sensitivities,
specificities and lnDORs between imaging techniques. A
p value<0.05 was considered statistically significant. All
meta-analyses were performed with SAS statistical software
(version 9.1, SAS institute, Cary, NC, USA).
Results
Literature search and study selection
The literature search yielded 6992 unique references
(Fig. 1). The reviewers selected 179 potentially relevant
articles after reading the titles and abstracts of which 46
papers were finally included [15, 19–63]. Twenty-eight
evaluated US, twelve evaluated CT, ten evaluated MRI and
five evaluated
1H-MRS. Eight papers compared two
imaging techniques [22, 23, 43, 47, 54, 58, 61, 62] and
one evaluated three techniques within the same population
[56] (Table 1). Two studies were published in German [28,
45] and the remaining in English.
Data extraction
Methodological quality An overview of the results is given
in Fig. 2. In general, 13 out of 46 (28%) studies fulfilled at
least 10 of the 13 methodological criteria [19, 20, 25, 29,
33, 34, 36, 38, 41, 44, 48, 49, 52]. A complete table of
individual study scores is available upon request from the
authors.
Patient characteristics The 46 papers comprised 4715
patients with a median study size of 81 patients (range 20–
589). Mean age reported by 37 studies was 44.5 years (range
11–89). Mean BMI reported by 18 studies was 26.6 kg/m
2
(range 15–54 kg/m
2). The male-to-female ratio reported in
40 studies was 1.62:1. Potential living liver donors consti-
tuted 34% of the total population (1593/4715). If specified,
the disease spectrum comprised most frequently chronic
hepatitis C (n=1040) and NAFLD/NASH (n=710). See also
Table 1.
Imaging features and evaluation US imaging features are
outlined in Online Resource 2. More than half (15/28) of
the studies used the widely accepted criteria for subjective
visual steatosis evaluation of bright liver with increased
liver-kidney contrast; blurring of intrahepatic vessels and
diaphragm and loss of echoes of posterior hepatic segments
[57, 60]. Two studies evaluated quantitative methods to
assess liver steatosis [30, 59].
CTimaging features are shown in Online Resource 3. Two
papers evaluated both contrast-enhanced CTand unenhanced
CT [22, 38]. All other papers evaluated unenhanced CT.
Average Hounsfield Units (HU) in selected regions of
interests (ROIs) from the liver were compared with average
HU values of ROIs from the spleen. The spleen was used as
an internal reference in all the papers included, either by
measuring the liver-minus-spleen attenuation value (L-S) or
the liver-to-spleen ratio (L/S). Two studies also evaluated
steatosis by subtracting hepatic blood attenuation from the
total hepatic attenuation using an algorithm. Four papers had
defined cut-off values prospectively [22, 43, 58, 61]. Six
papers defined optimal cut-off values retrospectively [15, 35,
38, 44, 52, 62]. The chosen cut-off values, however, varied
substantially.
MRI characteristics are outlined in Online Resource 4.
Magnetic field strength for all included papers was 1.5 Tesla.
Sequences used were T1-weighted dual spin echo, T1-
weighted dual gradient echo or T1-weighted spoiled gradient
echo for in-phase and out-of-phase (IP/OP) chemical shift
imaging. Two studies also evaluated T2-weighted fast spin
Eur Radiol (2011) 21:87–97 89echo imaging with and without fat suppression (±FS). Liver
steatosis was evaluated by the amount of signal intensity (SI)
loss on OP images compared with IP images and by SI
difference between FS and non-FS images. Exact measuring
methods, however, differed. Correction for T2* effects was
performed by d’Assignies et al [24]. Cho et al were the only
authors to define cut-off values prospectively [22].
1H-MRS imaging characteristics are outlined in Online
Resource 5. Magnetic field strengths were 1.5 T(3/5) and 3
T (2/5). Four papers used a point-resolved spectroscopic
sequence (PRESS), one in combination with chemical-shift
selective water suppression (CHESS). Krššák et al used a
stimulated echo acquisition mode (STEAM) sequence [41].
Voxel sizes varied from 18×18×18 mm to 30×30×40 mm.
Hepatic steatosis was evaluated by the ratio of lipid versus
water peaks and by the choline-to-lipid ratio. One paper
each corrected for T2 effects or T1 and T2 effects [24, 41].
All included studies defined cut-off values retrospectively.
Reference test Details of the reference test are outlined in
Online Resource 6. Cut-off values for grading steatosis
severity differed among the articles included, complicating
their comparison. Two studies compared semi-quantitative
visual analysis of steatosis with the automatic vacuole
segmentation method [24] or gas-liquid chromatography
[41]. Thirty studies examined the presence of fibrosis, 24
examined the presence of inflammatory activity and eight
studies examined the presence of iron.
Data for calculation of diagnostic accuracy Extraction of
2×2 accuracy data resulted in 48 complete data sets for
U S ;3 3f o rC T ;1 5f o rM R Ia n d7f o r
1H-MRS. For both
CT and MRI, 5 datasets were not included for analysis
because the examinations were visually assessed. This
resulted in 28 datasets being analysed for CT and 10
datasets being analysed for MRI. Datasets with TP and FN
only were also included for analysis: 4 for US and 1 for
CT. The number of datasets per cut-off group is noted in
Table 2. Six authors were contacted for completion or
verification of data; three answered of which one supplied
additional datasets. Three studies reported data-sets for
multiple readers [30, 31, 39].
9597 articles identified in
MEDLINE (January 1966-November 2009),
EMBASE (January 1980-November 2009),
COCHRANE and CINAHL
2605 excluded: duplicate references
6992 screened by title and abstract
179 selected for full-text review
46 included in systematic review
6813 excluded:
- No original research
- Animals, ex-vivo
- Not about fatty liver
- Not about diagnostic accuracy of US, CT, MRI or MRS
- No liver biopsy
- Sample size <10
133 excluded:
5      No evaluation of fatty liver by US, CT, MRI or 1H-MRS
14    No liver biopsy
9      Sample size <10
15    No gray scale real time (US)/ >120 kV (CT)/ <1 T (MRI/1H-MRS)
7      Criteria for positive index test not clearly described
10    Examination method for liver biopsy not clearly described
66    Construction of 2x2 contingency tables not possible
2      >1 index tests combined and results cannot be separated
5      No original research, animal study, ex-vivo
Fig. 1 Flow diagram of the articles included
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Study Technique Design
a No of patients
analysed (m/f)
Patient spectrum (n) Time interval between r
eference test and index test
Yajima 1983 US P 45 (ND/ND) 10 fatty liver; 8 chronic/acute hepatitis;
17 cirrhosis; 1 PSC; 9 other
≤14 days
Korte 1986 US P 100 (67/33) Suspected liver disease: alcohol abuse,
diabetes, obesity
Mean 1.9 weeks
Saverymuttu 1986 US P 85 (ND/ND) 50 ALD; 12 active hepatitis; 2 CPH;
3 PBC; 2 cryptogenic cirrhosis;
7 other; 4 normal
≤28 days
Lossner 1988 US P 187 (ND/ND) Suspected liver disease Mean 11 days
Joseph 1991 US P 50 (ND/ND) 30 ALD; 5 chronic persistent/reactive
hepatitis; 4 cryptogenic cirrhosis;
2 PBC; 9 other
0 days
Caturelli 1992 US P 35 (21/14) Suspected liver disease Unclear
Hultcrantz 1993 US P 83 (47/36) 45 fatty liver; 14 cirrhosis;
11 chronic inflammation; 13 other
0 days
Dietrich 1998 US P 68 (40/28) HCV Unclear
Kutcher 1998 US R 64 (39/25) HCV Unclear
Graif 2000 US P 28 (ND/ND) 12 HCV; 1 HBV; 1 PBC;
3 non alcoholic cirrhosis; 11 other
≤7 days
Rinella 2001 CT, MRI R 33 (19/14) Potential living liver donors Unclear
Mathiesen 2002 US P 165 (110/55) 65 NAFLD; 25 HCV; 14 ALD;
3 NASH; 3 AIH; 2 PBC; 1 A-1-antitrypsin
deficiency; 52 non-specific
87%≤28 days;
Saadeh 2002 US, CT, MRI P 25 (11/14) 8 NAFLD; 17 NASH ≤90 days
Kichian 2003 US R 49 (25/24) NAFLD Unclear
Rinella 2003 MRI ND 22 (13/9) 15 potential living liver donors; 7 NAFLD Unclear
Iwasaki 2004 CT P 266 (137/129) Living liver donors Unclear
Limanond 2004 CT R 42 (29/13) Potential living liver donors ≤28 days
Hepburn 2005 US R 164 (108/56) HCV Mean 1–2 months;
range 0–6 months
Kim SH 2005 US R 94 (71/23) Potential living liver donors Mean 39.9 days;
range 0–140 days
Kim SH 2006 MRI R 57 (40/17) Potential living liver donors Mean 14.5 days ±
18.8 days; range 0–124 d
Palmentieri 2006 US P 235 (127/108) 146 HCV; 30 HBV; 3 HCV/HBV;
33 NAFLD; 23 other
Unclear
Park 2006 CT P 154 (104/50) Potential living liver donors 0 days
Hamaguchi 2007 US P 94 (ND/ND) 68 NAFLD; 26 no disease ≤30 days
Hirche 2007 US P 122 (78/44) HCV Unclear
Lee JY 2007 US, CT R 589 (408/181) Potential living liver donors Unclear
Lee SW 2007 CT R 48 (44/4)
e Living liver donors 0 days
Perez 2007 US R 131 (78/53) 116 HCV; 5 HBV; 10 other ≤9 months
Bahl 2008 MRI P 52 (15/37) 29 NAFLD; 23 HCV/HIV ≤4 months
Chen 2008 US R 108 (75/33) 108 HCV Unclear
Cho 2008 MRI, CT R 131 (66/65) Liver resection for benign (5)
or malignant disease (126)
Median 17 days
Moura Almeida 2008 US P 105 (26/79) Bariatric surgery Unclear
Orlacchio 2008
1H-MRS P 30 (17/13) HCV ≤30 days
Yoshimitsu 2008 CT, MRI R 58 (35/23) 38 potential living liver donors;
20 liver metastases
≤14 days
Crum-Cianflone 2009 US P 216 (204/12) HIV Mean 5.2 months ±
3.6 months
Dasarathy 2009 US P 73 (48/25) 38 HCV; 21 NAFLD; 7 HBV; 7 other 0 days
d’Assignies 2009 MRI,
1H-MRS P 20 (15/5) 14 NAFLD; 6 ALD ≤60 days
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Sensitivity and specificity values including 95% confidence
intervals (CI) and significant differences (p<0.05) for the
imaging techniques are presented in Table 2 and in more
detail in the Online Resources 7–10.
Group 1 (cut-off values of >0%, >2% and >5%
steatosis) Sensitivity and specificity estimates were 73.3%
and 84.4% for US; 46.1% and 93.5% for CT; 82.0% and
89.9% for MRI and 88.5% and 92.0% for
1H-MRS,
respectively. The sensitivity of
1H-MRS was significantly
higher than that of US (p=0.04) and CT (p<0.01) and the
Table 1 (continued)
Study Technique Design
a No of patients
analysed (m/f)
Patient spectrum (n) Time interval between r
eference test and index test
Friedrich-Rust 2009 (Epub)
1H-MRS P 45 (1/44) PBC Median 21 days;
range 0–6 months
Kim DY 2009 (Epub) CT P 179 (115/64) Potential living liver donors 0 days
Krssak 2009 (Epub)
1H-MRS P 29 (16/13) HCV 0 days
McPherson 2009 MRI,
1H-MRS P 94 (66/28) 37 HCV; 23 fatty liver;
11 HBV; 7 AIH/PBC;
6 colorectal metastases; 10 other
Median 9 days
(range 0–209 days)
Mennesson 2009 MRI P 40 (20/20) 10 NAFLD; 9 ALD; 4 AIH;
4 cryptogenic liver disease; 6 other
0 days
O’Rourke 2009 MRI P 37 (23/14) colorectal liver metastases Unclear
Tobari 2009 US, CT R 118 (52/66) NASH ≤6 months
Webb 2009 US R 111 (60/51) 43 NAFLD; 56 HCV; 3 HBV; 9 other 0 days
Yamashiki 2009 US, CT P 78 (63/15) Potential living liver donors Unclear
Yu 2009 US P 180 (102/78) 171 fatty liver; 8 NASH; 1 cirrhosis Unclear
Epub Published online ahead of print, ND Not defined, BMI Body Mass Index, PSC Primary Sclerosing Cholangitis, ALD Alcoholic Liver
Disease, CPH Chronic Persistent Hepatitis, PBC Primary Biliary Cirrhosis, HBV Hepatitis B Virus, HCV Hepatitis C Virus, NASH Non-alcoholic
Steatohepatitis, HIV Human Immunodeficiency Virus, NAFLD Non-alcoholic Fatty Liver Disease, AIH Auto-immune Hepatitis
aP = prospective study design; R = retrospective study design
bUnless noted otherwise, data are mean ± standard deviation, with the range in parentheses
cMedian
dStandard error
e24 healthy individuals were matched with 24 patients for age and sex; Data for mean age ± SD are based on patient group (n=24)
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Withdrawals reported?
Reporting of uninterpretable results?
Clinical information available as in practice?
Blinded interpretation of reference test?
Blinded interpretation of index test?
Reference test reproducible?
Index test reproducible?
Reference test regardless of index test?
Complete sample verification?
Time interval ≤1 month?
Selection criteria specified?
Representative population?
Prospective study design?
Percentage of studies
yes
unclear
no
Fig. 2 Study design characteristics of the 46 studies included
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(p=0.02). No significant differences in specificity were
found. The lnDOR of
1H-MRS was significantly higher
compared with US (p=0.02) and CT (p=0.04).
Group 2 (cut-off values of >10%, >15% and >20%
steatosis) Sensitivity and specificity estimates were 90.5%
and 69.6% for US; 57.0% and 88.1% for CT; 90.0% and
95.3% for MRI and 82.6% and 94.3% for
1H-MRS,
respectively. CT had a significantly lower sensitivity com-
pared with US, MRI and
1H-MRS (p<0.01, p<0.01 and p=
0.02 respectively). Although US had a sensitivity comparable
to MRI and
1H-MRS, the specificity was significantly lower
than CT (p<0.01), MRI (p<0.01) and
1H-MRS (p=0.01).
The lnDOR of MRI was significantly higher than the lnDOR
for both US (p=0.05) and CT (p<0.01).
1H-MRS had a
significantly higher lnDOR than CT (p=0.03).
Group 3 (cut-off values of >25%, >30% and >33%
steatosis) Sensitivity and specificity estimates were 85.7%
and 85.2% for US; 72.0% and 94.6% for CT; 97.4% and
76.1% for MRI and 72.7% and 95.7% for
1H-MRS,
respectively. The sensitivity of MRI was significantly higher
than CT (p=0.01) and
1H-MRS (p=0.03). The specificity of
Table 2 Summary estimates of US, CT, MRI and
1H-MRS per
combined cut-off value group
Group 1: >0%, >2%, >5% steatosis as positives on biopsy
b
p-value
n
a Sensitivity (95% CI) US CT MRI
US 19 73.3 (62.2–82.1) –– –
CT 6 46.1 (22.2–71.8) NS ––
MRI 5 82.0 (63.7–92.2) NS 0.02 –
1H-MRS 3 88.5 (76.6–94.7) 0.04 <0.01 NS
n
a Specificity (95% CI) US CT MRI
US 19 84.4 (76.2–90.1) –– –
CT 6 93.5 (86.2–97.7) NS ––
MRI 5 89.9 (81.0–94.9) NS NS –
1H-MRS 3 92.0 (80.5–97.0) NS NS NS
n
a ln DOR (95% CI) US CT MRI
US 19 2.70 (1.97–3.43) –– –
CT 6 2.50 (1.13–3.87) NS ––
MRI 5 3.70 (2.50–4.90) NS NS –
1H-MRS 3 4.48 (3.15–5.81) 0.02 0.04 NS
Group 2: >10%, >15%, >20% steatosis as positives on biopsy
c
p-value
n
a Sensitivity (95% CI) US CT MRI
US 5 90.5 (79.3–96.0) –– –
CT 8 57.0 (51.5–62.3) <0.01 ––
MRI 2 90.0 (73.2–96.7) NS <0.01 –
1H-MRS 2 82.6 (61.8–93.3) NS 0.02 NS
n
a Specificity (95% CI) US CT MRI
US 5 69.6 (60.0–77.7) –– –
CT 8 88.1 (81.1–92.7) <0.01 ––
MRI 2 95.3 (83.2–98.8) <0.01 NS –
1H-MRS 2 94.3 (79.8–98.6) 0.01 NS NS
n
a ln DOR (95% CI) US CT MRI
US 5 3.09 (2.08–4.09) –– –
CT 8 2.28 (1.70–2.87) NS ––
MRI 2 5.22 (3.36–7.07) 0.05 <0.01 –
1H-MRS 2 4.36 (2.57–6.15) NS 0.03 NS
Group 3: >25%, >30%, >33% steatosis as positives on biopsy
d
p-value
n
a Sensitivity (95% CI) US CT MRI
US 19 85.7 (78.4–90.8) –– –
CT 15 72.0 (59.7–81.7) 0.03 ––
MRI 3 97.4 (83.5–99.6) NS 0.01 –
1H-MRS 2 72.7 (41.4–91.0) NS NS 0.03
n
a Specificity (95% CI) US CT MRI
US 19 85.2 (76.9–90.9) –– –
CT 15 94.6 (88.1–97.7) 0.03 ––
MRI 3 76.1 (49.6–91.2) NS 0.02 –
1H-MRS 2 95.7 (84.5–98.9) NS NS 0.04
n
a ln DOR (95% CI) US CT MRI
US 19 3.54 (2.80–4.29) –– –
CT 15 3.82 (2.79–4.85) NS ––
MRI 3 4.77 (2.46–7.08) NS NS –
1H-MRS 2 4.09 (2.15–6.04) NS NS NS
Group 4: >50%, >60%, >66% steatosis as positives on biopsy
n
a Sensitivity (95% CI)
US 9 91.1 (63.0–98.4)
CT 0 –
MRI 0 –
1H-MRS 0 –
n
a Specificity (95% CI)
US 9 91.9 (74.3–97.8)
CT 0 –
MRI 0 –
1H-MRS 0 –
n
a ln DOR (95% CI)
US 9 4.75 (3.41–6.08)
CT 0 –
MRI 0 –
1H-MRS 0 –
Ln DOR = logit sensitivity + logit specificity. NS = not significant
aNumber of datasets analysed
bFor CT and MRI: Only data for >0% and >5% available
cFor US and
1H-MRS: Only data for >10% steatosis available
dCT includes data for >25% and >30% steatosis only; MRI includes data
for >30% only;
1H-MRS includes data for >30% and >33% only
Table 2 (continued)
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and
1H-MRS (p=0.04). Further, the sensitivity for US was
significantly higher than for CT (p=0.03), the specificity for
US was significantly lower than for CT (p=0.03). Analysis
of the lnDOR did not show any significant differences.
Group 4 (cut-off values of >50%, >60% and >66%
steatosis) For this group, data analysis was possible for
US only. Sensitivity and specificity estimates were 91.1%
and 91.9% respectively.
Figure 3 shows the diagnostic performances (lnDOR) of
all imaging techniques per cut-off value group, illustrating
the better performance for both MRI and
1H-MRS
compared with US and CT.
Discussion
Our results show that MRI and
1H-MRS perform better
than US and CT over the total range of cut-off values that
were analysed. For the lower cut-off ranges, we found
significant differences in favour of both MRI and
1H-MRS.
These findings suggest that MRI and
1H-MRS also
perform better than US and CT for detecting separate disease
grades, especially for mild disease (<30% steatosis). This is
of value in clinical practice when an accurate estimation of
the amount of hepatic steatosis is needed. Additional benefits
of MRI and
1H-MRS over US are the quantitative measure-
ments which are less subject to inter- and intraobserver
variability [64]. For CT, drawbacks are the radiation
exposure and factors affecting the accuracy of the results,
such as imaging parameters or iron accumulation [11, 65].
Several limitations of our study must be considered.
First, the studies included showed great heterogeneity
regarding patient spectrum, reference test, index test and
data reporting. Therefore, comparison of separate disease
grades and sub-analysis of different aetiologies of steatosis
(e.g. NALFD/NASH versus HCV) was precluded. Stand-
ardisation of future study designs is needed to enable
these comparisons. Moreover, no studies compared all
four imaging techniques within the same population,
which would be the ideal study design. We were therefore
restricted to summarising accuracy data for each tech-
nique separately across all the studies included. These
indirect comparisons of studies, which showed substantial
methodological heterogeneity, might have biased our
results.
Second, we had to make the decision to group accuracy
results from different cut-off values into four subgroups to
enable meta-analysis and to reduce the number of summary
estimates and comparisons. The ideal situation would have
been to analyse accuracy results for each cut-off value
separately.
Third, a standard method for meta-analysis of diagnostic
studies is the summary Receiver Operating Characteristic
(sROC). For the sROC approach, a negative correlation
between the logit sensitivity and the logit specificity is
required [17]. As we did not find this negative correlation
in our data, plotting of sROC curves was not possible. We
therefore used the lnDOR to summarise our results.
Fourth, we did not analyse 3×3 or 4×4 data as the
reporting thereof was scarce. By dichotomising the results,
we lost information on the capability of imaging techniques
to diagnose the degree of steatosis.
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94 Eur Radiol (2011) 21:87–97A fifthlimitationwas thatwechose toexclude articleswith
1H-MRS as the reference standard [66–73].
1H-MRS is
increasingly used as a reference standard for steatosis
quantification since the results from the Dallas Heart Study
were published by Szczepaniak et al in 2005 [74]. However,
no clear consensus on this topic currently exists. The articles
that were excluded all compared MRI with
1H-MRS and
showed good correlations. Therefore, only a small number of
datasets were available for analysis of MRI. Additionally, the
included articles for MRI did not evaluate triple-echo, multi-
echo or multi-interference techniques, whereas the afore-
mentioned excluded articles did. Guiu et al recently
suggested that these new techniques should replace the
classical dual-echo chemical shift imaging methods, which
are not reliable for quantification of liver fat in the case of
liver iron overload because of T2* effects [75]. We believe
that the small number of available data in combination with
the techniques used could have negatively influenced our
accuracy results for MRI.
We therefore recommend that consensus on the role of
1H-MRS as the reference standard needs to be established.
For liver biopsy evaluation, we recommend using the
classification from Kleiner et al for a uniform grading of
hepatic steatosis [76].
In conclusion, we have shown that MRI and
1H-MRS
are most accurate for the detection of hepatic steatosis. For
future research, it is important to improve the study design
and reporting of accuracy results.
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